Lipid nanoparticle delivery vehicle is really simplifying a lot of therapeutics. Looking forward to seeing Moderna and Acuitas continue to build out the platform for more targeted or effective actuator delivery.
Most of the targeting today is happening through antibodies, but the majority of LNP delivery at this point is done passively without targeting mechanisms on the LNP (Needle injection point aside).
That's actually one advantage of CRISPR over just injecting mRNA - you can target specific cell-lines (Even if you change the genome of many cell types) by using cell-specific promoters for the edits you make instead of relying on surface affinity based targeting of the LNP.
Interesting resources:
[0]: https://www.nature.com/articles/nrd.2017.243 (General review 1)
[1]: https://www.frontiersin.org/articles/10.3389/fmolb.2020.5879... (General review 2)
[2]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498813/ (PCSK9 target again, but via siRNA actuator)
[3]: https://genomebiology.biomedcentral.com/articles/10.1186/s13... (Example of cell-specific CRISPR integration)
Not a book, but the News Features in Nature have a similar flavor, eg [1]. And for following up with the motivating article... well, there's sci-hub, for now.
[1] "The mysterious microbes that gave rise to complex life" https://www.nature.com/articles/d41586-021-01316-0 in https://www.nature.com/nature/volumes/593/issues/7859 .